Use of in vitro drug metabolism data to evaluate metabolic drug-drug interactions in man: The need for quantitative databases

Journal of Clinical Pharmacology

Volumn 41, Issue 4, 2001, Pages 368-373

  Rodrigues, A D ^a   Winchell, G A ^a   Dobrinska, M R ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; DESIPRAMINE; IMIPRAMINE; ITRACONAZOLE; KETOCONAZOLE; MIDAZOLAM; RITONAVIR; TRIAZOLAM; WARFARIN; ZOLPIDEM;

CATALYSIS; COMPETITIVE INHIBITION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG MARKETING; DRUG METABOLISM; FIRST PASS EFFECT; HUMAN; POLYPHARMACY; REVIEW;

CYTOCHROME P-450 ENZYME SYSTEM; DATABASES, FACTUAL; DRUG DESIGN; DRUG INTERACTIONS; HUMANS; ISOENZYMES; PHARMACOKINETICS; SENSITIVITY AND SPECIFICITY;

EID: 0035069388     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700122010212     Document Type: Review

References (47)

1. What are narrow therapeutic index drugs?
2. In vitro assessment of human cytochrome P450
3. Use of in vitro human metabolism studies in drug development: An industrial perspective
4. An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials
5. An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development: Experience within Hoffmann La Roche
6. Role of pharmacokinetics and metabolism in drug discovery and development
7. Integrated cytochrome P450 reaction phenotyping: Attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes
8. FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: Impact on labeling
9. In vitro metabolic interaction studies: Experience of the Food and Drug Administration
10. Assessment of the quality and quantity of drug-drug interaction studies in recent NDA submissions: Study design and data analysis issues
11. Quantitative prediction of in vivo drug metabolism and interactions from in vitro data
12. Prediction of pharmacokinetic alterations caused by drug-drug interactions: Metabolic interaction in the liver
13. The kinetics of enzyme inhibition
14. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: Prediction of in vivo drug-drug interactions
15. Inhibition and induction of human cytochrome P450 (CYP) enzymes
16. Preclinical and in vitro assessment of the potential of D0870, an antifungal agent, for producing clinical drug interactions
17. In vitro approaches to predicting drug interactions in vivo
18. Quantitative drug interactions prediction system (Q-DIPS): A computer-based prediction and management support system for drug metabolism studies
19. Enzyme-catalyzed processes of first-pass hepatic and intestinal extraction
20. Kinetics of drug-drug interactions
21. Warfarin-fluconazole III: A rational approach to management of a metabolically based drug interaction
22. First-pass metabolism of midazolam by the human intestine
23. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine
24. Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: The clinical dilemma of concurrent inhibition and induction
25. Is the role of the small intestine in first-pass metabolism overemphasized?
26. The role of the gut mucosa in metabolically-based drug-drug interactions
27. Pharmacokinetics of the newer benzodiazepines
28. 14C-midazolam in humans following oral dosing
29. 14C-alprazolam, a new anxiolytic and antidepressant in man
30. Clinical pharmacokinetics and pharmacodynamics of zolpidem: Therapeutic considerations
31. Triazolam disposition
32. Zolpidem: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential
33. Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole
34. Ketoconazole inhibition of triazolam and alprazolam clearance: Differential kinetic and dynamic consequences
35. Effect of itraconazole on the single oral dose pharmacokinetics of alprazolam
36. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole
37. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole and itraconazole
38. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes
39. Zolpidem metabolism in vitro: Responsible cytochromes, chemical inhibitors, and in vivo correlations
40. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily
41. Biotransformation of alprazolam by members of the human cytochrome P4503A subfamily
42. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4
43. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: Are the statins mechanistically similar?
44. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions
45. Human P450 metabolism of warfarin